Ensign Peak Advisors
FULC icon

Ensign Peak Advisors’s Fulcrum Therapeutics FULC Stock Holding History

Ensign Peak Advisors’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-15,610
Closed -$126K – 1944
2022
Q3 		$126K Sell
15,610
-1,590
-9% -$11.4K ﹤0.01% 2029
2022
Q2 		$84K Hold
17,200
– – ﹤0.01% 1992
2022
Q1 		$407K Buy
17,200
+2,230
+15% +$31.6K ﹤0.01% 1637
2021
Q4 		$233K Buy
+14,970
New +$297K ﹤0.01% 1890

Other funds holding FULC

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Ensign Peak Advisors's FULC Position: Q4 2022 in Review

Ensign Peak Advisors sold out of Fulcrum Therapeutics (FULC) in Q4 2022, closing a stake of 15,610 shares — an estimated $126K sold.

Ensign Peak Advisors first reported a position in FULC in Q4 2021 and held it in 4 quarters. The position peaked at $407K in Q1 2022. 110 funds tracked by Wall St. Rank hold FULC as of Q4 2022.

  • Ensign Peak Advisors reported no remaining Fulcrum Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Ensign Peak Advisors sold 15,610 Fulcrum Therapeutics shares in Q4 2022, an estimated $126K.
  • Ensign Peak Advisors first reported a position in Fulcrum Therapeutics in Q4 2021 and held it in 4 quarters.
  • Ensign Peak Advisors's Fulcrum Therapeutics position peaked at $407K in Q1 2022.
  • 110 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q4 2022.

Based on Ensign Peak Advisors's 13F filing for Q4 2022, filed 13 Feb 2023.